Navigation Links
Measuring molecules to improve drug design
Date:2/6/2009

CSIRO has patented an improved microscopy method for measuring the shapes and sizes of proteins which could help scientists create new pharmaceuticals that are a better match for the proteins they target.

The method, called Differential Aberration Correction (DAC) microscopy, measures distances at the molecular level in two and three dimensions using conventional fluorescence microscopy.

A special feature of the new method, written up recently in the Journal of Microscopy, is that it allows scientists to measure proteins in solution, which is how they exist in nature, instead of using coated or crystallised proteins as other techniques do. This is particularly important for rational drug design but has broader life sciences applications.

The leader of CSIRO's Biotech Imaging team, Dr Pascal Vallotton, says DAC microscopy measures distances a million times smaller than a tape measure can in nanometres rather than millimetres. One nanometre is one billionth of a metre.

"Just as a tailor measures up a person for a suit, we want to use our technique to measure accurate dimensions of proteins called membrane receptors," Dr Vallotton says.

"These proteins sit on cell boundaries, acting as gate-keepers, and they represent a class of biomolecules targetted by over 50 per cent of pharmaceuticals.

"Understanding the complex structures of these molecules and how new drugs affect their structure will help drug companies design more effective pharmaceuticals."

Cells are often viewed using conventional fluorescence microscopy. However, images obtained this way are inaccurate because light is bent differently for different wavelengths through the microscope. Several universities have attempted complex and onerous hardware-based solutions to try to fix this problem.

CSIRO researchers instead used a software-based approach that precisely corrects the distortion at every point in the image.

DA
'/>"/>

Contact: Carrie Bengston
Carrie.Bengston@csiro.au
61-293-253-224
CSIRO Australia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Atmospheric measuring device for understanding smog formation
2. Positron emission tomography superior to standard evaluation tools in measuring treatment response
3. New approach to measuring carbon in forests
4. Biosensor for measuring stress in cells
5. Measuring the stress of forested areas
6. Measuring calcium in serpentine soils
7. Measuring water from space
8. Clemson scientists shed light on molecules in living cells
9. New molecules discovered that block cancer cells from modifying cell DNA
10. Curry-derived molecules might be too spicy for colorectal cancers
11. New book presents methods to poke and prod individual molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a technology ... measures the overall facial feature of a person such ...
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Nov. 12, 2013 One of the most comprehensive ... today, demonstrating an unprecedented level of genetic variation that ... ovarian cancer. The study highlights potential new pathways for ... multiple disease sites may be required for effective targeted ...
... as clear as glass, or why bakers use sugar, even ... in the American Chemical Society,s (ACS,) latest Bytesize Science ... . "Everything that happens in the kitchen is science," ... of it, you,re going to have more power over your ...
... protein, they tend to eat a small amount at ... at dinner. New research presented today at The ... eating high protein sausage and egg-based breakfasts curbed hunger ... and syrup) or skipping breakfast, in 18-55-year-old women., ...
Cached Biology News:Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 2Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment 3
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: ... sclerosis (MS), today announced financial and operational results for ... demonstrated the ability to safely affect MS progression in ... of the Canadian/European trial (MAESTRO-01) in the second half ...
... LONDON and WASHINGTON, March 17 Gentag, Inc. (Gentag) ... VCG & Associates Inc. and Talisman Management Ltd. to ... of all or parts of its IP portfolio. ... pharmaceutical and medical diagnostic uses on a global or ...
... AMGN ) will present at the Cowen and ... at the Boston Marriott Copley Place, Boston, Mass., beginning at ... President of North American Commercial Operations, will present. Live audio ... can be accessed from Amgen,s Web site, www.amgen.com , ...
Cached Biology Technology:BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Gentag, Inc. Engages US and UK Firms to Explore Strategic Options 2
... Product Mouse monoclonal [SPM278] to ... Small cell lung carcinoma N592 live cells ... with Human. Not yet tested in other ... of the major glycoproteins of basement membrane, ...
TLN2 Antibody...
Chicken polyclonal to Thaumatin 2 ( Abpromise for all tested applications). Antigen: Full length Thaumatin 2...
XIAP Antibody...
Biology Products: